Lysogene
IPOParis, France · $22.0M raised
- Headquarters
- Paris
- Employees
- 11–50
- Business Model
- B2B
- Website
- lysogene.com
- Total Funding
- $22.0M
- Last Round
- $22.0M Series AMay 2014
- Rounds
- 1
About
Lysogene is a clinical-stage gene therapy company focused on treating orphan diseases of the central nervous system (CNS). The company has built a unique capability to deliver gene therapies directly to the brain using AAV vectors, targeting rare neurological conditions with high unmet medical need. Lysogene's programs included treatments for GM1 gangliosidosis and other lysosomal storage disorders. The company was founded by CEO Karen Aiach and has been listed on Euronext in Paris.
Summary
Lysogene is a Biotech company based in Paris, France. It has raised $22.0M in total across 1 round, most recently a $22.0M Series A round in May 2014. Investors include Sofinnova Partners, European Investment Bank and Bpifrance.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Dec 2021
Sign up to see all 3 rounds
Series A through Post-IPO Debt — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/lysogene"><img src="https://indexed.vc/api/badge/company/lysogene" alt="Lysogene on Indexed.vc" width="260" height="76" /></a>